FDA Assigns September 29, 2014 Prescription Drug User Fee Act Goal...

RALEIGH, N.C. & TARRYTOWN, N.Y.-- -- Salix Pharmaceuticals, Ltd. and Progenics Pharmaceuticals today announced that the Food and Drug Administration has informed Salix that the supplemental New Drug Application for RELISTORA Subcutaneous Injection, 20 mg/ml, for the treatment of opioid-induced constipation in patients taking opioids for chronic ... (more)

http://ift.tt/1sGvE2p